Francis Crick Institute
In New TRACERx Data, Personalis MRD Test Shows Improved Sensitivity With Potential Clinical Impact
Premium
The data, some of the first available for the firm's NeXT Personal test, indicated that its higher analytical sensitivity could lead to better risk prediction than competing tests.
Personalis MRD Assays to Support UK's TRACERx ctDNA Monitoring Study
The ongoing lung cancer study, which has employed other assays in the past, will now use the Personalis NeXT Personal platform to monitor for recurrence after surgery.
AstraZeneca, ArcherDx Partner on Minimal Residual Disease Monitoring for Lung Cancer Drug Trials
ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).
ArcherDx, University College London, Crick Institute Partner on Lung Cancer Recurrence Research
The partners will develop patient-specific assays based on ArcherDx's anchored multiplex PCR technology to track disease recurrence in lung cancer patients.